(Length of Interview: 17 min)

Peter Pinto highlights the paradigm shift to the use of new imaging technology for a more accurate diagnosis of prostate cancer. Targeted MRI/Ultrasound (MR/US) guided biopsy vs TRUS biopsy, full body imaging options such as PET, and Axumin® (fluciclovine F 18)  as a staging tool, with mention of metabolic and focal imaging are part of this comprehensive interview. As technique and interpretation are standardized, the goal is to offer treatment that is most applicable to a personal cancer diagnosis.

Biographies:

Peter A. Pinto, MD, Board Certified Urologic Surgeon, Head, Prostate Cancer Section, Principal Investigator, Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH

John Fortin, Retired Healthcare Actuary, Fellow in the Society of Actuaries, patient-advocate and prostate cancer survivor.